Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.
The POC assay is being developed under a DoD contract to detect pathogens that may pose a threat to national security and public health.
LabCorp will provide clinical reference laboratory testing services as part of the contract, whose completion date is expected to be Sept. 30, 2019.
CLIP program requirements are comparable to requirements for CLIA accreditation but might be modified to meet Department of Defense mission needs.
Martin Edelman will investigate whether cancer associated macrophage-like cells can determine whether small or indeterminate lung nodules are cancerous or benign.
The two-year contract will be used to develop a portable prototype to quickly identify critical infectious pathogens considered threatening to war combatants.
The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.
The base term for the contract, which is for medical surgical products, is 14 months with eight one-year and one 10-month option periods.